Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Biotech financing: divide and reset

Nature Biotechnology volume 43, pages 1028–1034 (2025)Cite this article

Today’s uniquely challenging biotech climate may result in a more resilient sector.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Venture totals and round sizes.
Fig. 2: 1Q25 IPOs and M&A trends.
Fig. 3: Chinese licensing deals.
Fig. 4: Top biopharma technologies for venture.

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Biotech financing: divide and reset. Nat Biotechnol 43, 1028–1034 (2025). https://doi.org/10.1038/s41587-025-02723-8

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-025-02723-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing